CD4 and cancer: Although the neoantigens were selected based on their likelihood to stimulate CD8+ T cells, CD4+ T cells were the dominant population responding to the vaccines, lending credence to the essential role of activating CD4+ T cells for the development of a promising cancer vaccine, but also raising questions with regard to the efficiency of cross-presentation that results from peptide vaccination.